Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084 15/01/2026

7,450 USD (-3,25%)

(-3,25%) 15/01/2026

Grafiek Vanda Pharmaceuticals Inc

Grafiek Vanda Pharmaceuticals Inc

1 dag1d -3,25%
1 week1w 1,64%
1 maand1m 12,03%
3 maanden3m 41,37%
6 maanden6m 54,89%
1 jaar1j 67,79%
5 jaar5j -46,63%

Vanda Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

8 januari 2026 · Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder · Persbericht

31 december 2025 · Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness · Persbericht

15 december 2025 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

11 december 2025 · Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference · Persbericht

4 december 2025 · FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness · Persbericht

28 november 2025 · Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness · Persbericht

18 november 2025 · Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting · Persbericht

5 november 2025 · Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference · Persbericht

29 oktober 2025 · Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results · Persbericht

22 oktober 2025 · Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 · Persbericht

Profiel Vanda Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.vandapharma.com

Hoofdzetel: Washington, Washington Dc Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe